Pleiotropic effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in pulmonary diseases: A comprehensive review. (February 2015)

• Record Type: Journal Article
• Authors: Krishna, Rama K.; Issa, Omar; Saha, Debjit; Macedo, Francisco Yuri B.; Correal, Barbara; Santana, Orlando
• Is Part Of: Pulmonary pharmacology & therapeutics. Volume 30(2015:Feb.)
• Page Start: 134
• Page End: 140
• Publication Date: 2015-02
• Subjects: Statins -- Pleiotropic effects -- Pulmonary disease -- Comprehensive review; Respiratory organs -- Diseases -- Chemotherapy -- Periodicals; 615.7205
• DOI: 10.1016/j.pupt.2014.08.006
• Languages: English
• ISSNs: 1094-5539

Abstract

Abstract: The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) are used extensively in the treatment of hyperlipidemia. They have also demonstrated a secondary benefit in a variety of other disease processes, actions which are known as pleiotropic effects. Review of the current pulmonary literature suggests a potential advantage of statin usage in a variety of pulmonary conditions. Our paper serves as a focused discussion on the pleiotropic effects of statins in the most common pulmonary disorders.